Preventing antibodies to infliximab in patients with Crohn's disease: Optimize not immunize

This publication has 15 references indexed in Scilit:

• The safety profile of infliximab for Crohn's disease in clinical practice: The Mayo clinic experience in 500 patients
  Gastroenterology, 2003
• Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
  Gastroenterology, 2003
• Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
  New England Journal of Medicine, 2003
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
  Published by Elsevier ,2002
• Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
  Gastroenterology, 2001
• Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
  Gastroenterology, 1999
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
  Arthritis & Rheumatism, 1998
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
  New England Journal of Medicine, 1997
• Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
  Proceedings of the National Academy of Sciences, 1989